866-997-4948(US-Canada Toll Free)

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Oct 2016

Category :

Pharmaceutical

No. of Pages : 59 Pages

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2016, provides in depth analysis on Catenin Beta 1 (Beta Catenin or CTNNB1) targeted pipeline therapeutics.

The report provides comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)
- The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Catenin Beta 1 (Beta Catenin or CTNNB1) Overview 7
Therapeutics Development 8
Catenin Beta 1 (Beta Catenin or CTNNB1) - Products under Development by Stage of Development 8
Catenin Beta 1 (Beta Catenin or CTNNB1) - Products under Development by Therapy Area 9
Catenin Beta 1 (Beta Catenin or CTNNB1) - Products under Development by Indication 10
Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Catenin Beta 1 (Beta Catenin or CTNNB1) - Products under Development by Companies 13
Catenin Beta 1 (Beta Catenin or CTNNB1) - Products under Development by Universities/Institutes 15
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development 24
Dicerna Pharmaceuticals, Inc. 24
Marina Biotech, Inc. 25
Propanc Health Group Corp 26
Warp Drive Bio, Inc. 27
Catenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles 28
Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Liver Fibrosis - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
CEQ-508 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
exisulind - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
nefopam hydrochloride - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
PRP - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Small Molecules for Inflammation - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules to Inhibit Beta-Catenin for Oncology - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Catenin Beta 1 (Beta Catenin or CTNNB1) - Dormant Projects 43
Catenin Beta 1 (Beta Catenin or CTNNB1) - Featured News & Press Releases 44
Sep 07, 2016: Propanc Files Application for Orphan Medicinal Product Designation in the EU for Pancreatic Cancer 44
Aug 23, 2016: Propanc Enters Into Contract Manufacturing Agreement With AmatsiQBiologicals 45
Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream 46
Jun 13, 2016: Propanc Provides Shareholder Update on PRP Development Activities 47
Apr 19, 2016: Propanc Files Two More Patents Citing New Compositions of Proenzymes for Cancer Treatment 48
Mar 02, 2016: Propanc Confirms PRP Response to Broad Range of Cancer Indications; Sets Date for Scientific Advice Meeting with UK Regulators 49
Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics 50
Feb 04, 2016: Propanc Discovers PRP Dramatically Suppresses Cancer Stem Cells 51
Nov 17, 2015: Propanc Demonstrates Significant Anti-Tumor Efficacy in Pancreatic and Ovarian Cancer Preclinical Models; Files Patent Specifying New Therapeutic Target Dose Range 52
Aug 31, 2015: Propanc Receives Patent Approval in Key Jurisdiction 53
Aug 05, 2015: Marina Biotech's CEQ508 Granted FDA Fast Track Designation for Familial Adenomatous Polyposis 54
Jul 09, 2015: Propanc Identifies Positive Signals for Efficacy from Pilot Animal Studies 54
May 06, 2015: Dicerna Announces Potent, Durable Knockdown of Gene Expression in Non-human Primates with DsiRNA-EX Conjugates Being Investigated for Treatment of Primary Hyperoxaluria Type 1 (PH1) 55
May 04, 2015: Dicerna to Present at the 17th Annual TIDES: Oligonucleotide and Peptide Therapeutics From Research through Commercialization Conference 56
Apr 10, 2015: Dicerna Presents New -catenin Data from Multiple Tumor Models at the 2015 RNA & Oligonucleotide Therapeutics Meeting at Cold Spring Harbor Laboratory 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 5

List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Dicerna Pharmaceuticals, Inc., H2 2016 24
Pipeline by Marina Biotech, Inc., H2 2016 25
Pipeline by Propanc Health Group Corp, H2 2016 26
Pipeline by Warp Drive Bio, Inc., H2 2016 27
Dormant Projects, H2 2016 43

List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Mechanism of Actions, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Routes of Administration, H2 2016 20
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *